USD10
Actions EVMN
À propos de EvommuneEvommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
USD10
Actions EVMN
À propos de EvommuneEvommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Statistiques
FEN ÊTRE DE TRADING
Fermé
OUVRE À
30 mars at 13:30 UTC+0
Capitalisation boursière
801,52 M $US
PRIX D'OUVERTURE
Données insuffisantes
BAS (1 an)
13,89 $US
ÉLEVÉ (1 an)
33,20 $US
BAS (24 h)
Données insuffisantes